

Appl. No. : 09/653,267
Amendment Dated : March 30, 2005
Reply to OfficeAction of : February 22, 2005

Docket No. 0113873.120 US2

Amendment of the claims: This listing of the claims will replace all prior versions, and listings, of the claims in this application.

Listing of claims:

1-105. (canceled)

106. (previously presented) A pharmaceutical or cosmetic composition comprising:

(a) an oleaginous pharmaceutical or cosmetic carrier comprising, by weight:

75-99 percent of a hydrophobic solvent, and

1-25 percent of a solidifying agent, wherein said solidifying agent consists essentially of a long chain fatty alcohol having at least 15 carbon atoms in its carbon backbone and a fatty acid having at least 18 carbons in its carbon backbone,

wherein the carrier is semi-solid at rest and liquefies upon application of shear forces thereto; and

(b) a therapeutically or cosmetically effective amount of a biologically active substance.

107. (previously presented) A pharmaceutical or cosmetic composition comprising:

(a) an oleaginous pharmaceutical or cosmetic carrier comprising, by weight:

75-99 percent of a hydrophobic solvent, wherein the hydrophobic solvent comprises an omega-3 or omega-6 oil, and

1-25 percent of a solidifying agent, wherein said solidifying agent is selected from the group consisting essentially of long chain fatty alcohols having at least 15 carbon atoms in its carbon backbone and fatty acids having at least 18 carbons in its carbon backbone, and wherein the carrier is semi-solid at rest and liquefies upon application of shear forces thereto; and

(b) a therapeutically or cosmetically effective amount of a biologically active substance.

108. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein the carrier comprises, by weight, 4-12 percent of a solidifying agent and 88-96 percent of a hydrophobic solvent.

109. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein the carrier comprises, by weight, 5-10 percent of the solidifying agent.

110. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein solidifying agent has melting point of less than 80°C.

111. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein the hydrophobic solvent comprises at least 6% of an omega-3 or omega-6 oil.

112. (previously presented) The pharmaceutical or cosmetic composition of claim 106, wherein said hydrophobic solvent is selected from the group consisting of marine animal derived oils, terrestrial animal derived oils, mineral oils, silicone oils and plant-derived oils.

113. (previously presented) The pharmaceutical or cosmetic composition of claim 107, wherein said hydrophobic solvent further comprises an oil selected from the group consisting of partially or fully hydrogenated plant-derived oils, marine animal-derived oils and terrestrial animal derived oils, mineral oils, emollients, and silicone oils.

114. (currently amended) The pharmaceutical or cosmetic composition of claim 106, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, *syzgium aromaticum* oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojoba jojoba oil.

115. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein said fatty acid or said fatty alcohol has at least one alkyl group side chain in its carbon backbone.

116. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β .

117. (previously presented) The pharmaceutical or cosmetic composition claim 106 or 107, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

118. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein said solidifying agent includes a 12-hydroxy fatty acid.

119. (previously presented) The pharmaceutical or cosmetic composition of claim 106, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

120. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein said biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-nucleoside reverse transcriptase inhibitor, a nucleoside-analog reverse transcriptase inhibitor, a protease inhibitor, a non-steroidal anti-inflammatory drug, an immunosuppressant, an antihistamine agent, an anti-inflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent.

121. (currently amended) The pharmaceutical or cosmetic composition of claim 120, wherein:

(a) said antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and ~~semi-synthesie~~ semi-synthetic penicillins, ~~beta-lactames~~ beta-lactams, quinolones, ~~fluoroquinolnes~~ fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, ~~erytromyein~~ erythromycin and ~~elinndamyein~~ clindamycin;

(b) said free radical generating agent is benzoyl peroxide;

Appl. No. : 09/653,267
Amendment Dated : March 30, 2005
Reply to OfficeAction of : February 22, 2005

Docket No. 0113873.120 US2

(c) said antifungal agent is selected from the group consisting of azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazol, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B and potassium iodide;

(d) said antiviral agent is selected from the group consisting of flucytosine (5FC), vidarabine, acyclovir and gancyclovir;

(e) said nucleoside-analog reverse transcriptase inhibitor is selected from the group consisting of Zidovudine, Stavudine and Lamivudine;

(f) said non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of Nevirapine and Delavirdine;

(g) said protease inhibitor is selected from the group consisting of Saquinavir, Ritonavir, Indinavir, Nelfinavir, Ribavirin Amantadine, Rimantadine and Interferon;

(h) said immunosuppressant is selected from the group consisting of Clobetasol propionate, Halobetasol propionate, Betamethasone dipropionate, Betamethasone valerate, Fluocinolone acetonide, Halcinonide, Betamethasone valerate, Fluocinolone acetonide, Hydrocortisone valerate, Triamcinolone acetonide, Hydrocortisone and hexachlorobenzene;

(i) said anti-inflammatory agent is a vitamin B3 or a derivative thereof;

(j) said retinoid agent is selected from the group consisting of isotretinoin, adapalene and tretinoin;

(k) said tar agent is selected from the group consisting of coal tar and cade oil;

(l) said antihistamine agent is doxepine hydrochloride;

Appl. No. : 09/653,267
Amendment Dated : March 30, 2005
Reply to OfficeAction of : February 22, 2005

Docket No. 0113873.120 US2

(m) said antipruritic agent is crotamiton; and
(n) said scabicide agent is selected from the group consisting of benzyl benzoate, malathion and crotamiton.

122. (previously presented) The pharmaceutical or cosmetic composition of claim 106 or 107, wherein said biologically active substance is effective in the treatment of a disease or disorder selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.